Phthalates impair germ cell number in the mouse fetal testis by an androgen- and estrogen-independent mechanism.

Abdelali Lehraiki, Chrystèle Racine, Andrée Krust, René Habert, Christine Levacher

To cite this version:

HAL Id: inserm-00438655
http://www.hal.inserm.fr/inserm-00438655
Submitted on 9 Dec 2009

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers. L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.
Phthalates Impair Germ Cell Number in the Mouse Fetal Testis by an Androgen- and Estrogen-Independent Mechanism

Abdelali Lehraiki,*‡‡ Chrystèle Racine,*‡‡ Andréè Krust,§ René Habert,*‡‡ and Christine Levacher*‡‡†

*Laboratory of Gonad Differentiation and Radiobiology, Stem Cells and Radiation Service, Institute of Cellular and Molecular Radiation Biology, Life Sciences Division, Commissariat à l’Energie Atomique, BP 6, 92265 Fontenay-aux-Roses, France; ‡Université Paris Diderot-Paris 7, BP 6, 92265 Fontenay-aux-Roses, France; §Unité 967, INSERM, BP 6, 92265 Fontenay-aux-Roses, France; and †Institut de Génétique et de Biologie Moléculaire et Cellulaire, (CNRS, INSERM, UDS, Collège de France), BP 10142, 67404 Illkirch-Strasbourg, France

Received June 10, 2009; accepted July 7, 2009

Phthalates esters are a class of environmental endocrine disrupting chemicals which are mainly used as plasticizers in PVC plastics. They are found in numerous consumer goods and, because they are not covalently bound to the plastic product, they can leach out over time from these products and can be ingested (Silva et al., 2004). After absorption, phthalates are rapidly hydrolyzed by esterases in the gut and other tissues into a monoester, which is the active molecule (Latin, 2005). For example, di-(2-ethylhexyl) phthalate (DEHP), one of the most widely used phthalates, is metabolized to its monoester metabolite, mono-(2-ethylhexyl) phthalate (MEHP), which is a recognized active testicular toxicant (Fisher, 2004).

Numerous studies in the rat have shown that in utero exposure to phthalates results in male reproductive disorders including altered seminiferous cord formation, multinucleated gonocyte (MNG) formation, epididymal agenesis, nipple retention, reduced ano-genital distance, hypospadias and cryptorchidism (Foster, 2006; Gray et al., 2006), and also reduction of fetal testosterone production and Leydig cell Insl3 gene expression (Lehmann et al., 2004; McKinnell et al., 2005; Sharpe and Skakkebaek, 2008), all these effects attesting to a profound alteration of testis development.

During fetal and neonatal development of the testis (Jost and Magre, 1993; Olaso and Habert, 2000), after migration of the primordial germ cells (PGCs) from extra-embryonic mesoderm to the genital ridge at embryonic day 11.5 (E11.5) in the mouse (Yoshimizu et al., 2001), the differentiating Sertoli cells (Wilhelm et al., 2007) surround the germ cells, therefore called gonocytes, to form the seminiferous cords from E12.5. The gonocytes divide actively, many of them undergoing apoptosis by E12.5-14.5 (Wang et al., 1998) and then enter a quiescent period (Nagano et al., 2000; Vergouwen et al., 1991). After birth, they resume mitosis while a second wave of apoptosis occurs (Boulouge, 2003; Wang et al., 1998) (Fig. 1) and start to differentiate into spermatogonia. The interstitial region contains mesenchymal cells and steroid-secreting Leydig cells from E12.5 (Livera et al., 2006; O’Shaughnessy et al., 2005). Interactions between the different cell lineages occur early in morphogenesis of the testis and are crucial for its normal development. Androgens mediate a wide range of developmental and physiological responses that are critical for the male reproductive and nonreproductive system (Sharpe, 2006; Welsh et al., 2008). During fetal life, testis development is
physiologically modulated by, among other factors (Olaso and Habert, 2000), estrogen and androgen because estrogen receptor beta (ERβ) and androgen receptor (AR) inactivation lead to an increase in germ cell number (Delbes et al., 2004; Merlet et al., 2007), whereas testosterone production is enhanced by ERα inactivation (Delbes et al., 2005).

Until now, the mechanisms of action of phthalates have not been elucidated. MEHP activates peroxisome proliferators–activated receptor (PPAR-α) in cell transactivation assays (Corton and Lapinskas, 2005) but phthalate-treated PPAR-α−/− mice develop toxic lesions in the testis (Ward et al., 1998), suggesting that phthalates can act through PPAR-α–independent pathways in mediating testicular toxicity (Bhattacharya et al., 2005). In addition, phthalates show little estrogenic activity (Harris et al., 1997; Takeuchi et al., 2005), but can also reduce estradiol production (Lovekamp-Swan and Davis, 2003), and there is a growing consensus that they are antiandrogenic (Hu et al., 2009). However, phthalates and their mono-phthalate metabolites do not bind to AR (Parks et al., 2000), indicating that they are not direct AR antagonists. Most studies investigating the in utero effects of phthalates have been performed in the rat in vivo and have focused on the phthalate-induced suppression of testosterone production and Leydig cell aggregation (Fisher et al., 2003; Mylchreest et al., 1999). This has led to a hypothesized causal relationship between reduced testosterone production, altered fetal testicular development and reduced sperm counts in adulthood (Scott et al., 2007; Skakkebaek et al., 2001). However, an in vitro study from our laboratory on human fetal testis evidenced a reduction of the number of gonocytes by MEHP in the absence of any alteration of testosterone production (Lambert et al., 2009). A recent study in the mouse demonstrated also that, as in the rat, in utero DBP exposure increases the number of MNGs, but unlike the rat this response occurs in the absence of measurable disruption of testicular testosterone concentrations (Gaibo et al., 2007).

Therefore, we used organ culture of fetal mouse testis to establish that there is no relationship between phthalate-induced alterations of fetal steroidogenesis and gonocyte development, unlike what has been concluded from observations in the rat. Furthermore, using mice deficient for AR or ER, we showed that the phthalate-induced alterations are independent of these receptors.

**MATERIAL AND METHODS**

**Chemicals and solutions.** The culture medium was phenol red-free Dulbecco’s Modified Eagle Medium/Ham F12 (1:1) (Invitrogen, Carlsbad, CA) supplemented with 80 μg/ml gentamicin (Invitrogen), Ovine LH (oLH; NIH/LH S19; 1.01 U/mg) was a gift from Dr A.F. Parlow (National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD). MEHP was from TCI Europe (Antwerp, Belgium). A stock solution (4mM) was made up in dimethyl sulfoxide and then diluted in culture medium. db-cAMP (N6, 2′-O-dibutyryl-cAMP) was from Sigma Aldrich (St Louis, MO).

**Animals.** C57Bl/6 and transgenic mice were housed under controlled photoperiod (lights on 08:00-20:00) with ad libitum access to tap water and a soy and alfalfa-free breeding diet (Global diet 2019, Harlan Teklad, Indianapolis, IN). Mice lacking ERα (ERα−/− or ERβ (ERβ−/−) were produced by Dupont et al. (2000) and generously provided by Pierre Chambron (Institut de Genetique et de Biologie Moleculaire et Cellulaire, Illkirch, France). Androgen-insensitive Tfm mice (C57Bl/6J-129.Cg-Eda-Tfl/1ArTflm Tfm Y) were from the Jackson Laboratory (Bar Harbor, ME). Transgenic animals were genotyped as described previously (Delbes et al., 2004, 2005; Merlet et al., 2007). Males were caged with females overnight and the day following overnight mating was counted as E0.5. Pregnant mice were killed by cervical dislocation on E13.5, E15.5, or E18.5 and the fetuses were quickly removed from the uterus. Fetuses were dissected under a binocular microscope, their sex was determined on the basis of the gonad morphology and the testes were collected from male fetuses. All animal studies were conducted in accordance with the NIH Guide for Care and Use of Laboratory Animals.

**Organ culture and treatment.** Organ cultures were performed as previously described (Livera et al., 2006). Briefly, intact E13.5 testes associated with their mesonephros were placed on 10-mm-diameter Millicell CM filters (Millipore, Billerica, MA) (pore size 0.45 μm). Testes from E15.5 and E18.5 were isolated and cut into six and eight pieces, respectively, and all the pieces from the same testis were placed on a single Millicell filter. The filter bearing the pieces of testes was floated on 0.4 ml of culture medium in tissue culture fluid, embedded in paraffin, and cut into 5-μm sections. For RNA analysis, testes were immediately dry frozen with liquid nitrogen and stored at −80°C. The entire media were kept at −20°C until testosterone radioimmunoassay. The data were obtained from at least three independently repeated cultures with fetuses from different litters.

**Immunohistochemistry.** Serial sections were mounted on slides, deparaffinized and rehydrated. They were immunostained by a standard procedure as previously described (Delbes et al., 2007). To unmask the MVH (mouse vasa homolog) protein, sections were microwaved at 750 W for 5 min and at 450W for 3 min in 10mM citrate buffer solution (pH 6.0). For all immunohistochemical procedures, slides were incubated in 0.3% H2O2 for 15 min and in 5% bovine serum albumin in phosphate-buffered saline for 30 min. The primary antibody was detected by incubation with an appropriate biotinylated secondary antibody (1:200; Vector Laboratories, Burlingame, CA) for a further 30 min at room temperature followed by incubation with avidin-biotin-peroxidase complex (Vector Laboratories) for 30 min. DAB (Vector Laboratories) was used as the chromogen and hematoxylin as the nuclear counterstained. Negative controls were done by omitting the primary antibody.
**Testicular cell counting.** Germ cells and Leydig cells were identified by immunohistochemical detection of MVH and 3βHSD, respectively. The counting was done as previously described (Delbes et al., 2004). All counts were performed blind using Histolab analysis software (Microvision Instruments, Evry, France).

**Measurement of germ cell apoptosis.** Because cleaved caspase-3 is involved in most of the apoptotic pathway, we chose its detection as a marker of apoptosis (Delbes et al., 2004). Gonocytes were distinguished by combining staining for AMH (a Sertoli-specific marker) and cleaved caspase-3 (rabbit polyclonal anti-cleaved caspase-3 1:100; Cell Signaling Technology, Beverly, MA). Cleaved caspase-3 was localized first using DAB (Vector Laboratories) and AMH was then detected using VIP substrate (Vector Laboratories). The percentage of apoptotic germ cells was determined by counting the stained and unstained gonocytes in all sections mounted.

**Measurement of BrdU incorporation index.** The percentage of germ cells in S-phase was evaluated by measuring the BrdU (5-bromo-2′-deoxyuridine) incorporation by immunohistochemical methods using the Cell Proliferation Kit (GE Healthcare, Buckinghamshire, UK) according to the manufacturer’s recommendations. BrdU (1%) was added to the culture medium 3 h before the end of culture. BrdU incorporation into proliferating cells was detected by immunocytochemistry using a mouse anti-BrdU antibody and a peroxidase-linked anti-mouse IgG. Sertoli cells and gonocytes were distinguished by combining staining for AMH (a Sertoli-specific marker) and BrdU. BrdU localization was performed first using DAB (Vector Laboratories) and AMH was then detected using VIP substrate (Vector Laboratories). The BrdU incorporation index was obtained by a blind counting of at least 1000 Sertoli cell or 400 gonocyte stained and unstained nuclei in five nonconsecutive sections from every treatment group experiment. Histolab analysis software was used for counting (Microvision Instruments, Evry, France).

**Measurement of testosterone production.** Testosterone secretion into the medium was determined in duplicate by direct radioimmunoassay, without extraction as previously described (Habert and Picon, 1984).

**RNA extraction and reverse transcription.** Total RNA was extracted using the RNeasy Plus mini-Kit (Qiagen, Courtaboeuf, France) and reverse transcribed using the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Courtaboeuf, France) according to the manufacturer’s instructions.

**Real-time quantitative PCR.** Q-PCRs were performed on an ABI PRISM 7000 Sequence Detector System using a TaqMan PCR Master Mix (Applied Biosystems). The primers and probes used were assays on demand designed by Applied Biosystems (Table 1). The primers and probes used for 3βHSD and external standard luciferase were described (Baker and O’Shaughnessy 2001; Evry, France). Measurements, Evry, France).

<table>
<thead>
<tr>
<th>Gene full name</th>
<th>Gene symbol</th>
<th>Applied Biosystem accession number</th>
</tr>
</thead>
<tbody>
<tr>
<td>3-Hydroxy-3-methylglutaryl coenzyme A reductase</td>
<td>HMG-CoA reductase</td>
<td>Mm01282499_m1</td>
</tr>
<tr>
<td>Steroidogenic acute regulatory protein</td>
<td>StAR</td>
<td>Mm0041558_m1</td>
</tr>
<tr>
<td>P450 side-chain cleavage enzyme</td>
<td>Cyp11a1</td>
<td>Mm 00490735_m1</td>
</tr>
<tr>
<td>P450 17α hydroxylase</td>
<td>Cyp17a1</td>
<td>Mm00484040_m1</td>
</tr>
<tr>
<td>Steroid 5-alpha reductase</td>
<td>Srd5a1</td>
<td>Mm00614213_m1</td>
</tr>
<tr>
<td>P450 aromatase</td>
<td>Cyp19a1</td>
<td>Mm00484049_m1</td>
</tr>
<tr>
<td>Luteinizing hormone receptor (LH-R)</td>
<td>Lhgr</td>
<td>Mm0042931_m1</td>
</tr>
<tr>
<td>Insulin-like growth factor 3</td>
<td>Ins3</td>
<td>Mm01340353_m1</td>
</tr>
</tbody>
</table>

**RESULTS**

**Effects of MEHP on Leydig Cells**

**Basal and LH-stimulated testosterone production.** In wild-type control testes, as shown in Figure 2, the presence of 200μM MEHP during 3 days of culture in basal medium induced a high and significant time-dependent stimulation of testosterone production in E13.5 and E18.5 testes. When the testes were cultured in the presence of 100 ng/ml oLH, testosterone production was increased fourfold in E13.5 testes and more than 10-fold in E18.5 testes compared with basal conditions. In these conditions, the daily testosterone production in E13.5 testes was unaffected by 200μM MEHP, but was significantly decreased in a time-dependent manner in E18.5 testes with a strong inhibition on D3.

As expected (Delbes et al., 2005), testosterone production was significantly higher in ERα−/− animals than in respective wild-type controls in basal conditions. The invalidation of ERα did not modify the stimulatory and inhibitory effects of MEHP on testosterone secretion in E18.5 testes in basal and LH-stimulated conditions, respectively (Fig. 2).

**Number of Leydig cells.** Compared with controls, the number of Leydig cells was not significantly modified after exposure to 200μM MEHP in the presence or absence of LH at all the studied stages (Fig. 3A). In addition, no abnormal distribution or clustering of the Leydig cells was observed in any condition (Fig. 3B).

**Leydig cell gene expression.** Because MEHP had no effect on Leydig cell number, we hypothesized that its effect on steroidogenesis was due to the modulation of the expression of genes coding for proteins involved in cholesterol and testosterone biosynthesis or metabolism. Therefore, mRNA expression of key genes was analyzed by real-time PCR (Fig. 4). In basal conditions, significant increases in gene expression likely to explain the stimulation of testosterone production by MEHP were observed at the level of HMG-CoA reductase and Cyp17a1 in E13.5 testes and StAR and Cyp17a1 in E18.5 testes (Fig. 4). In LH-stimulated conditions, the decrease in testosterone production in E18.5 testes was related to a 40–50% reduction of the expression levels of all the genes tested, except 5-alpha-reductase, whereas they were not significantly altered in E13.5 testes (Fig. 4) in agreement with the lack of
change in testosterone production. Aromatase (Cyp19a1) and 5-alpha-reductase are required in the conversion of testosterone to estradiol and dihydrotestosterone, respectively, and could modulate the amount of testosterone secreted. The expression of aromatase was decreased in both the absence and presence of LH at all ages studied (Fig. 4), but the expression of 5-alpha-reductase was never modified. The expression of LH-R (LH receptor, Lhcgr) in E13.5 and E18.5 testes was not modified by MEHP in the absence of LH in the culture medium, but was significantly reduced in its presence (Fig. 4). Interestingly, the expression of Insl-3, the protein which plays a major role in testis descent, was decreased by MEHP in all studied conditions except in E13.5 testes cultured in the absence of LH (Fig. 4).

\textit{db-cAMP–stimulated testosterone production.} In an attempt to elucidate whether the decrease in LH receptor expression was involved in the inhibition of LH-stimulated production.

\begin{figure}[h]
\centering
\includegraphics[width=\textwidth]{fig2.png}
\caption{Effect of MEHP on testosterone secretion by fetal testes from wild-type and ERα−/− mice in organ culture. Testes at E13.5 (upper panels) and E18.5 (lower panels) were cultured for 3 days (D1–D3) in control medium or in the presence of 200\(\mu\)M MEHP. Cultures were performed in the absence (left panels) or presence (right panels) of 100 ng/ml oLH as indicated. Values are mean ± SEM from 4 to 18 cultures. \(*p < 0.05, **p < 0.01, ***p < 0.001\) versus corresponding control value in the paired Student’s \(t\)-test. \(*p < 0.05\) in the unpaired Student’s \(t\)-test for different genotypes.}
\end{figure}

\begin{figure}[h]
\centering
\includegraphics[width=\textwidth]{fig3.png}
\caption{Effect of MEHP on the number and histological appearance of Leydig cells in mouse testes in organ culture. (A) Number of Leydig cells in E13.5 and E18.5 testes after 3 days of culture in the absence (white bars) or presence of 200\(\mu\)M MEHP (black bars) and in the absence or presence of 100 ng/ml oLH. Values are mean ± SEM from four to five cultures. There was no significant difference between control and MEHP. (B) Leydig cells (arrows), as revealed by immunostaining of 3β-HSD, in mouse testes at E18.5 after 3 days of culture in control medium or in the presence of 200\(\mu\)M MEHP. No morphological alteration or distribution was detectable after MEHP exposure.}
\end{figure}
testosterone production by MEHP at E18.5, we evaluated the effect of MEHP on db-cAMP–stimulated testosterone production. The inhibition of testosterone production by MEHP (Fig. 5) was similar to that obtained with LH, which means that it exerts its rate-limiting inhibitory effect downstream from LH-R.

Effects of MEHP on Sertoli Cell Proliferation and Function

MEHP did not alter the proliferation of Sertoli cells because the BrdU-labeling index was not modified after 3-day treatment with 200μM MEHP at any age studied (results not shown). However, immunostaining of AMH clearly showed that its Sertoli cell content was markedly decreased compared with control in E13.5, E15.5, and E18.5 testes after 3 days of treatment with 200μM MEHP (Fig. 6).

Effects of MEHP on Germ Cells

Gonocyte distribution and morphology. After 3 days of culture, the integrity of the seminiferous cord structure was maintained in both control and treated testes at all fetal and neonatal stages studied and at all concentrations of MEHP tested (Fig. 7). However, with 200μM MEHP all the gonocytes have disappeared in E13.5dpc testes (see further) and, in E15.5 and E18.5 testes, the gonocytes stayed aggregated in the center of the cord (Figs. 6E and 6F).

MNGs occurred spontaneously in E15.5 and E18.5 control testes after 3 days of culture, that is, during and after the quiescent period, and their number was increased significantly by 200μM MEHP with the greatest increase observed in E18.5 testes (Fig. 7A). E18.5 testes from ER<sup>β</sup> or AR (Tfm) deficient mice, showed similar increase in MNCs (for ER<sup>β</sup>: 1.84±0.33% in control vs. 8.79±0.94 in MEHP treated, n=9; for Tfm: 2.15±0.52% in control vs. 12.5±2.91 in MEHP treated, n=4) than the wild-type (Fig. 7A: 2.02±0.32% in control vs. 8.79±0.89 in MEHP treated, n=9). In E13.5 testes, no MNG was detected after 1 or 3 days of culture in control conditions or after 24-h treatment with 20μM MEHP (Fig. 7A).

Number of gonocytes. Because MEHP affected testosterone production differently in the presence and absence of LH, we evaluated its effect on gonocytes in these two conditions (Fig. 7B). The presence of LH and, consequently, a high level of testosterone production, did not modify the number of gonocytes in E13.5 and E18.5 control conditions or after 24-h treatment with 20μM MEHP (Fig. 7A).
number of gonocytes by ~40–50% after 3 days of culture (D3), that is, 24 h after resuming mitosis and apoptosis. As expected (Delbes et al., 2004), in testes from E18.5 the number of gonocytes was higher in ERβ−/− mice than in wild-type mice (ERβ+/+) after 3 days of culture. After MEHP treatment, the number of gonocytes was reduced in the same manner in E18.5 testes from wild-type mice and from ERβ−/− or Tfm mice (Fig. 8). Taken together, these results demonstrate that MEHP reduces the number of germ cells throughout fetal/neonatal life except during the quiescent period, independently of the level of testosterone production and of ER and AR pathways.

Germ cell proliferation and apoptosis. The decrease in the number of gonocytes in MEHP-exposed testes could be induced by an increased rate of apoptosis or by a reduced rate of proliferation. The effect of MEHP on proliferation and apoptosis was therefore studied by assessing the percentage of BrdU (Fig. 7D) and cleaved caspase 3–positive (Fig. 7C) gonocytes, respectively.

MEHP greatly increased the rate of apoptotic gonocytes at all the ages studied (Fig. 7C). At the same time, the proliferation of the gonocytes was increased by 40% in E13.5 after 24-h exposure to 20µM MEHP (Fig. 7D), but was reduced by 60% in E18.5 testes after 3 days of exposure to 200µM MEHP. Taken together, these results show that MEHP reduces the number of gonocytes essentially by increasing apoptosis.

DISCUSSION

We have previously shown that ER and AR are involved in fetal testis development (Delbes et al., 2004, 2005; Merlet et al., 2007). Using an organotypic culture system of fetal testis from wild-type mice or from mice deficient for ER or AR, we present here the first demonstration that phthalate-induced alterations of both steroidogenesis and germ cell number do not involve ER and AR.

Steroidogenesis

Our findings show that testicular alteration of steroidogenesis by phthalates during fetal life is very complex. We report here for the first time a stimulatory effect of MEHP on testosterone production in fetal mouse testis and that MEHP can stimulate, inhibit or have no effect on testosterone production depending on the age of the testis at explantation and on the culture conditions. These results differ from those of numerous experiments conducted in the rat that have led to the conclusion that the main deleterious effect of phthalates concerns their antiandrogenic capacity, because testosterone production by the fetal testis is reduced after in utero (Fisher et al., 2003; Foster, 2006) or in vitro exposure (Chauvigné et al., 2009; Hallmark et al., 2007) to phthalates. Furthermore, recent experiments on in utero exposure to DBP in the mouse (Gaido et al., 2007) and on in vitro exposure of fetal human testis to MBP (Hallmark et al., 2007) or MEHP (Lambrot et al., 2009) failed to observe any inhibition of testosterone production or changes in the expression of the steroidogenic enzymes. Moreover, phthalates can stimulate steroidogenesis in prepubertal testis in vivo (Lin et al., 2008), in mouse gonadal cell lines or primary Leydig cell cultures (Ge et al., 2007). In all these cases, the mechanisms involved have not been fully elucidated.

In the present study, the MEHP-induced stimulation of steroidogenesis can be ascribed mainly to an increased
transcription of p450C17 and also of HMGCoA-reductase, as reported in gonadal cell lines (Gunnarsson et al., 2008) or of StAR, depending on the developmental stage. In contrast, the inhibitory effect of MEHP on steroidogenesis was obtained by a reduction of the level of the mRNAs of the main genes involved in testosterone biosynthesis while, in the rat it was mainly ascribed to p450C17 and P450scc (Chauvigné et al., 2009; Culty et al., 2008; Hallmark et al., 2007). Additionally, in E18.5 testes, MEHP reduced the expression of LH-R, but this does not seem to be involved in the reduction of steroidogenesis. The reduction of aromatase activity could participate in the stimulation of testosterone production in the absence of LH, that is, in conditions of low testosterone production, mostly by reducing the inhibition of steroidogenesis by estradiol (Delbes et al., 2006, 2007) via ERα (Delbes et al., 2005), the reduction of testosterone transformation being probably negligible because intratesticular estradiol concentration is very low (Delbes et al., 2004). However, we show here that the ERα pathway (Delbes et al., 2006) is involved neither in the stimulatory nor in the inhibitory effects of MEHP on testosterone secretion.

The present results provide new insights into the mechanisms underlying the effects of phthalates on fetal testicular steroidogenesis, because they prove that they are independent of the ER pathway but depend on other factors: 1) the developmental stage, which modulates the maturation and the limiting steps of the steroidogenic pathway, the LH level and the cholesterol availability (present results; Gunnarsson et al., 2008; Hallmark et al., 2007); 2) the species because, in vitro, unlike the rat (Chauvigné et al., 2009) and the results we present here in the mouse, human fetal testis is not sensitive to phthalate in terms of steroidogenesis (Hallmark et al., 2007; Lambrot et al., 2009). Aggregation of Leydig cells and even their presence in the seminiferous tubules have also been reported to be a prominent consequence of in utero (Lin et al., 2008; Mahood et al., 2005) or in vitro (Chauvigné et al., 2009; Hallmark et al., 2007) exposure of rat fetal testis to phthalates, but was not observed in the present experiments on mouse testis in vitro or in vivo (Gaido et al., 2007) or in human fetal testis in vitro (Hallmark et al., 2007; Lambrot et al., 2009).

The importance of an alteration of Leydig cell status during fetal life is related to its possible role in inducing...
cryptorchidism and hypospadias (Foster et al., 2001; Henley and Korach, 2006) and concerns not only testosterone but also Ins3 production. Underdeveloped gubernaculum (Barlow and Foster, 2003) and reduced Ins3 expression have been observed following fetal exposure to phthalates in male rats (Lague and Tremblay, 2008; Lehmann et al., 2004; McKinnell et al., 2005). Indeed, Ins3 mRNA was also reduced in the mouse testes after MEHP exposure, except in E13.5 testis in basal conditions when maturation/stimulation of Leydig cells is low.

Gonocyte Development

Our findings clearly show that phthalates strongly impair germ cell development in the fetal mouse testis in vitro during critical time-specific windows. In our model, MEHP reduces the number of gonocytes by inducing massive apoptosis during early fetal and late fetal/neonatal life, in relation to the high mitotic and apoptotic activity during these periods. During the quiescent phase between E15.5 and E19.5 (day of birth), due to the naturally low apoptotic activity of the gonocytes, phthalates did not significantly reduce their number. This can be compared with the low sensitivity to retinoic acid (Livera et al., 2000) and transforming growth factor (TGFβ1) (Olaso et al., 1998) of rat germ cells during their quiescent period. These results are in accordance with the few studies that have previously focused on the modification of the number of gonocytes by phthalates in other species, with the mouse being particularly sensitive: in the rat in vivo, the number of gonocytes is reduced at E21.5 when the animals are treated from E13.5, but not when they are treated later (Ferrara et al., 2006); in vitro MEHP reduces the number of gonocytes in the fetal testis of E14.5 (Chauvigné et al., 2009) and of PN3 neonate (Li and Kim, 2003); lastly, phthalates have been shown recently to reduce the number of gonocytes in human fetal testis in vitro at an early stage (Lambrot et al., 2009).

Apoptosis could result from a direct effect of phthalates on the gonocytes or from an indirect effect via other cell types. The fact that the deleterious effects of MEHP on the gonocytes are similar whether it stimulates or inhibits steroidogenesis suggests that they do not involve antiandrogenic effects as postulated in the rat (Chauvigné et al., 2009; Scott et al., 2007; Skakkebaek et al., 2001). This hypothesis was strengthened by the fact that MEHP reduces the number of gonocytes in a similar fashion in Tfm mice. The gonocytes of ERβKO mice were also similarly affected, demonstrating that MEHP does not also act via ER, directly, or indirectly via the modulation of aromatase. Therefore, even though we demonstrated previously that ERβ and AR pathways physiologically control fetal germ cell number (Delbes et al., 2004; Merlet et al., 2007), we can definitively eliminate a direct or indirect effect of MEHP on fetal germ cells via antiandrogenic/estrogenic effects.

In the rat, germ cell apoptosis could also be induced by Sertoli cells (Fisher et al., 2003; Kleymenova et al., 2005) which are targets of MEHP because, although their proliferation is not affected, they exhibit a reduction in AMH content. Various nonexclusive pathways have been postulated to be involved in MEHP-induced germ cell apoptosis, such as the TRAIL (McKee et al., 2006) and NF-kB (Rasoulpour and Boekelheide, 2005) pathways and the Fas/FasL system (Giammona et al., 2002; Yao et al., 2008). Lastly, our in vitro observations in the mouse that phthalates disturb gonocyte migration and increase the occurrence of MNGs in late fetal life are in agreement with in vivo observations in the mouse (Gaido et al., 2007) and rat (Ferrara et al., 2006; Kleymenova et al., 2005).

The phthalate-induced alteration in the number of gonocytes at the fetal and neonatal stage could compromise subsequent reactivation of germ cell proliferation and development during puberty as in the rat (Ferrara et al., 2006) and lead to altered fertility in adulthood. Furthermore, the impairment of differentiation of gonocytes is to some extent reminiscent of the failure of fetal gonocyte differentiation that is thought to lead to formation of CIS (carcinoma in situ) cells and subsequent testicular germ cell tumors in humans (Rajpert-De Meyts, 2006). Further studies are needed to establish if in utero exposure to phthalates leads, in the mouse, to altered fertility or occurrence of tumors in adulthood.

CONCLUSION

The present data define specific critical periods of sensitivity of fetal mouse testis to MEHP and clearly establish that the effects of phthalates on steroidogenesis are unrelated to those on gonocyte development. We demonstrated that the strong deleterious effect of phthalates on the germ cell lineage that is observed in various mammalian species is independent of any

FIG. 8. Involvement of ER and AR in the effects of MEHP on the number of gonocytes in fetal testes. Testes at E18.5 from wild-type, ERβ−/− and Tfm mice were cultured for 3 days in control medium (white bars) or in the presence of 200 μM MEHP (black bars). At the end of the culture, total gonocytes were counted as described in Material and Methods. Values are mean ± SEM from four to nine cultures. *p < 0.05, **p < 0.01 versus corresponding control value in the paired Student’s t-test for wild-type mice; *p < 0.05 in the unpaired Student’s t-test for two different genotypes.
antiandrogenic effects and that the phthalates are neither estrogenic nor antiandrogenic because their effects do not involve, directly or indirectly, ER or AR.

FUNDING

Université Paris Diderot, by the Institut National de la Santé et de la Recherche Médicale; Commissariat à l’Énergie Atomique; Agence Nationale de la Recherche Project Santé-Environnement et Santé-Travail (ANR2007SEST01901); and Ministère de l’Éducation Nationale de la Recherche et de la Technologie (237132006) fellowship to A.L.

ACKNOWLEDGMENTS

We thank Prof. P. Chambon for providing transgenic mice (Institut de Génétique et Biologie Moléculaire et Cellulaire, Illkirch, France) and Prof A. Payne (Stanford University Medical Center, CA) for providing the anti-3HSD antibody. We also thank C. Chamaillard for expert technical assistance, V. Neuville, S. Leblay, and S. Rodrigues for animal care and A. Gouret for secretarial assistance.

REFERENCES


